These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [New development in the treatment of breast cancer. II. Future anti-HER2 therapy]. Yamashita T; Iwata K Gan To Kagaku Ryoho; 2009 Dec; 36(13):2551-4. PubMed ID: 20104676 [No Abstract] [Full Text] [Related]
7. Neratinib (HKI-272) in the treatment of breast cancer. López-Tarruella S; Jerez Y; Márquez-Rodas I; Martín M Future Oncol; 2012 Jun; 8(6):671-81. PubMed ID: 22764764 [TBL] [Abstract][Full Text] [Related]
8. New omics information for clinical trial utility in the primary setting. Damia G; Broggini M; Marsoni S; Venturini S; Generali D J Natl Cancer Inst Monogr; 2011; 2011(43):128-33. PubMed ID: 22043059 [TBL] [Abstract][Full Text] [Related]
9. Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy. Kyrochristos ID; Ziogas DE; Roukos DH Med Res Rev; 2019 May; 39(3):1205-1227. PubMed ID: 30417574 [TBL] [Abstract][Full Text] [Related]
10. Comprehensive strategy for the design of precision drugs and identification of genetic signature behind proneness of the disease-a pharmacogenomic approach. Iyer PM; Karthikeyan S; Sanjay Kumar P; Krishnan Namboori PK Funct Integr Genomics; 2017 Jul; 17(4):375-385. PubMed ID: 28470340 [TBL] [Abstract][Full Text] [Related]
11. Where to with HER2? Sledge GW Clin Breast Cancer; 2010 Feb; 10(1):18. PubMed ID: 20133253 [No Abstract] [Full Text] [Related]
13. Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer. Lumachi F; Chiara GB; Foltran L; Basso SM Cancer Genomics Proteomics; 2015; 12(6):385-90. PubMed ID: 26543084 [TBL] [Abstract][Full Text] [Related]
14. HER2 status and benefit from adjuvant trastuzumab in breast cancer. Paik S; Kim C; Wolmark N N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751 [No Abstract] [Full Text] [Related]
15. Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations. Kourie HR; Chaix M; Gombos A; Aftimos P; Awada A Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):947-57. PubMed ID: 27284682 [TBL] [Abstract][Full Text] [Related]
16. Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets. Cho WC; Roukos DH Expert Rev Anticancer Ther; 2013 Jan; 13(1):5-8. PubMed ID: 23259420 [No Abstract] [Full Text] [Related]
17. New protein kinase inhibitors in breast cancer: afatinib and neratinib. Zhang X; Munster PN Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047 [TBL] [Abstract][Full Text] [Related]
18. Gene Expression Assays in Early-Stage Breast Cancer. Sparano JA Oncology (Williston Park); 2018 Oct; 32(10):510-2. PubMed ID: 30334241 [No Abstract] [Full Text] [Related]
19. Emerging Therapeutic Strategies in Breast Cancer. Cox K; Alford B; Soliman H South Med J; 2017 Oct; 110(10):632-637. PubMed ID: 28973703 [TBL] [Abstract][Full Text] [Related]
20. Neratinib after trastuzumab in patients with HER2-positive breast cancer. Hasegawa T; Uno H; Wei LJ Lancet Oncol; 2016 May; 17(5):e176. PubMed ID: 27301038 [No Abstract] [Full Text] [Related] [Next] [New Search]